NBTX Nanobiotix S.A.
Price Chart
Executive Summary
Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raising ~$100M in gross proceeds. The offering was priced at a 14.92% discount to the VWAP, and proceeds will primarily fund the Nanoprimer platform and general corporate purposes, extending the cash runway into 2029.
Key Financial Metrics
Actionable Insight
The offering provides a substantial cash runway into 2029, reducing near-term financing risk. However, the 14.92% discount and full exercise of the over-allotment option signal aggressive capital raising. Monitor for any updates on the Nanoprimer platform pipeline and potential clinical catalysts that could offset dilution overhang.
Key Facts
- Total gross proceeds of ~$100M (€86.1M) from the global offering.
- 2,218,467 ordinary shares and 345,099 pre-funded warrants issued.
- Offering price of $38.98 per ADS (€33.60 per ordinary share), a 14.92% discount to the 3-day VWAP.
- Proceeds allocated: <10% for JNJ-1900 (NBTXR3), 50-60% for Nanoprimer and other platforms, 30-40% for general corporate purposes.
- Cash runway extended into 2029 based on current burn rate.
- Underwriters' option to purchase additional ADSs was fully exercised.
- Jefferies, TD Cowen, and Stifel acted as global coordinators and joint bookrunners.
Financial Impact
Gross proceeds of ~$100M from the offering, with a 14.92% discount to the 3-day VWAP. Dilution from 2,218,467 shares and 345,099 pre-funded warrants.
Risk Factors
- Dilution from the issuance of 2,218,467 shares and 345,099 pre-funded warrants.
- 14.92% discount to VWAP may pressure the stock in the near term.
- Proceeds allocated broadly, with management retaining discretion; execution risk on platform development.
- No specific clinical catalysts or revenue disclosed in this filing.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
Press Release
| $40.50 $35.20 | ▼ −13.09% | ▼ −13.56% | $35.88 (−11.41%) |
|
May 22, 2026
18d ago
|
Press Release
| $40.80 $36.76 | ▼ −9.90% | ▼ −11.11% | $35.88 (−12.06%) |
|
May 21, 2026
19d ago
|
Press Release
| $40.18 $40.41 | ▼ −0.57% | ▲ +1.03% | $35.88 (+10.70%) |
|
May 21, 2026
19d ago
|
Press Release
| $40.18 $40.41 | ▼ −0.57% | ▲ +1.03% | $35.88 (+10.70%) |
|
May 21, 2026
20d ago
|
Press Release
| $40.18 $40.40 | ▼ −0.55% | ▲ +1.30% | $35.88 (+10.70%) |
|
May 20, 2026
20d ago
|
Press Release
| $40.18 $40.40 | ▼ −0.55% | ▲ +1.30% | $35.88 (+10.70%) |
|
May 18, 2026
22d ago
|
6-K
| $49.48 $40.80 | ▼ −17.54% | ▼ −19.16% | $35.88 (−27.49%) |
|
May 17, 2026
23d ago
|
Press Release
| $49.48 $40.80 | ▼ −17.54% | ▼ −19.16% | $35.88 (−27.49%) |
|
May 4, 2026
5w ago
|
Press Release
| $34.77 $48.24 | ▲ +38.74% | ▲ +36.76% | $35.88 (+3.19%) |
|
Apr 20, 2026
7w ago
|
6-K
| $31.91 $33.11 | ▲ +3.76% | ▲ +2.85% | $35.88 (+12.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access